NASDAQ: OKYO
Okyo Pharma Ltd Earnings Dates, Reports, Calls

Okyo Pharma earnings were -$4.7M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest OKYO earnings report on Mar 31, 2025 announced Q1 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Mar 31, 2025, OKYO reported annual earnings of -$4.7M, with -72% growth.

OKYO earnings history

Current Revenue
$0.0
Current Earnings
-$4.7M
Current Profit Margin
0%

OKYO Return on Equity

Current Company
N/A
Current Industry
-60.2%
Current Market
31.3%

OKYO undefined

Current Company
-180.4%
Current Industry
-2.5%
OKYO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when OKYO announces earnings.

OKYO undefined

Current Company
127.79%
Current Industry
5.8%
OKYO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

OKYO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
OKYO-$7.09M-$4.71MN/A-$0.20
PLRX-$210.49M-$219.52MN/A-$3.60
ABOS-$132.35M-$136.67MN/A-$2.28
CELU-$43.55M-$57.89MN/A-$2.64
NAUT-$59.26M-$65.69MN/A-$0.52

Okyo Pharma Earnings Reports & History FAQ

What were Okyo Pharma's earnings last quarter?

Okyo Pharma (NASDAQ: OKYO) reported Q1 2025 earnings per share (EPS) of N/A, up N/A year over year. Total OKYO earnings for the quarter were N/A. In the same quarter last year, Okyo Pharma's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Okyo Pharma stock.

Is Okyo Pharma profitable or losing money?

As of the last Okyo Pharma earnings report, Okyo Pharma is currently losing money. Okyo Pharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$4.71 million, a 72.03% decrease year over year.

What was OKYO's earnings growth in the past year?

As of Okyo Pharma's earnings date in Q3 2025, Okyo Pharma's earnings has grown year over year. OKYO earnings in the past year totalled -$4.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.